EP0507772A1 - Cellule eucaryote non melanocytique exprimant de maniere constitutive la tyrosinase humaine biologiquement active, et son utilisation - Google Patents
Cellule eucaryote non melanocytique exprimant de maniere constitutive la tyrosinase humaine biologiquement active, et son utilisationInfo
- Publication number
- EP0507772A1 EP0507772A1 EP90907793A EP90907793A EP0507772A1 EP 0507772 A1 EP0507772 A1 EP 0507772A1 EP 90907793 A EP90907793 A EP 90907793A EP 90907793 A EP90907793 A EP 90907793A EP 0507772 A1 EP0507772 A1 EP 0507772A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- tyrosinase
- cell
- cells
- melanocytic
- human tyrosinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 101000606090 Homo sapiens Tyrosinase Proteins 0.000 title claims abstract description 52
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims abstract description 66
- 238000000034 method Methods 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 168
- 108060008724 Tyrosinase Proteins 0.000 claims description 62
- 102000003425 Tyrosinase Human genes 0.000 claims description 61
- 239000002299 complementary DNA Substances 0.000 claims description 36
- 108020004414 DNA Proteins 0.000 claims description 23
- 239000013604 expression vector Substances 0.000 claims description 16
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 6
- 241000238631 Hexapoda Species 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 108091081024 Start codon Proteins 0.000 claims description 4
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims description 3
- 241000701447 unidentified baculovirus Species 0.000 claims description 3
- 238000011144 upstream manufacturing Methods 0.000 claims description 3
- 210000005253 yeast cell Anatomy 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 2
- 201000001441 melanoma Diseases 0.000 description 34
- 230000000694 effects Effects 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 239000000427 antigen Substances 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 14
- 210000002950 fibroblast Anatomy 0.000 description 13
- 239000000284 extract Substances 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 239000000049 pigment Substances 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- 210000002780 melanosome Anatomy 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 239000006166 lysate Substances 0.000 description 6
- 230000008099 melanin synthesis Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 210000002752 melanocyte Anatomy 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000000636 Northern blotting Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 101000608782 Mus musculus Tyrosinase Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 3
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 229960004441 tyrosine Drugs 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- 230000001894 hemadsorption Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000000684 melanotic effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 108010079892 phosphoglycerol kinase Proteins 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- RQPKNXVVIBYOBX-KDBLBPRBSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-2-(dihydroxyamino)-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.ON(O)[C@H](C(O)=O)CC1=CC=CC=C1 RQPKNXVVIBYOBX-KDBLBPRBSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 101710187578 Alcohol dehydrogenase 1 Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 101710167911 Repressible acid phosphatase Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 208000006431 amelanotic melanoma Diseases 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004395 cytoplasmic granule Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000003370 dye binding method Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/18—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with another compound as one donor, and incorporation of one atom of oxygen (1.14.18)
- C12Y114/18001—Tyrosinase (1.14.18.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- Melanocytes and cells of melanocyte lineage are distinguished by their capacity to synthesize the pigment melanin.
- Melanin production is primarily regulated by the enzyme tyrosinase (monophenol, 3, 4-dihydroxyphenylalanine: oxygen oxidoreductase, EC 1.14.18.1) .
- melanin synthesis occurs principally in melanosomes which are specialized organelles. Thus, melanin synthesis is generally restricted to melanosome-containing melanocytic cells.
- This application describes the isolation of a full length of cDNA clone encoding human tyrosinase. Isolation is achieved by using a probe whose sequence is homologous to the Pmel 34 cDNA sequence described by Kwon et al. (1, 35, 37). Moreover, transfection and expression of this new human tyrosinase cDNA clone in mouse fibroblasts induced pigmentation in a cell type which normally does not synthesize melanin. Levels of tyrosinase activity in transfected fibroblasts were equivalent to tyrosinase levels in highly pigmented human melanoma cell lines.
- tyrosinase-positive fibroblast cell lines demonstrate that melanin synthesis can take place in cells that are not melansome-containing. As a result, we have a tool in which to study the regulation, transport and processing of tyrosinase synthesis.
- This invention provides a non-melanocytic eucaryotic cell constitutively expressing biologically active human tyrosinase. This invention also provides such a cell which expresses biologically active human tyrosinase under conditions such that the cell produces melanin.
- this invention provides a method of producing biologically active human tyrosinase and melanin.
- j Figure 1 Nucleotide and predicated amino acid sequence of BBTY-1 cDNA. The nucleotide sequence is numbered in the 5* to 3' direction. Residues of a predicted signal peptide are indicated by negative numbers, and a cleavage site by a vertical arrow. Termination site (TAA) and polyadenylation signal (869 to 875) are underlined. Potential glycosylation sites are designated by dashed lines.
- FIG. 1 Northern blot analysis of poly (A + )-selected RNA (4 ⁇ g/lane) from two pigmented melanoma cell lines that express tyrosinase and the B cell lymphoma cell line Daudi. The blot was hybridized with the 3 P-labeled insert of pBBTY- 1. Lanes: 1) SK-MEL-23 melanoma; 2) SK-MEL-19 melanoma; and 3) Daudi.
- LpcTYR and LpcTYW cell lines were transfected with BBTY-1 inserted sense or antisense into the expression vector pcEXV3.
- LpcTYR-1 and LpcTYR-2 are subclones of LpcTYR. 1) LpC cell pellet (non- pigmented) ; 2) LpcTYW (non-pigmented) ; 3) LpcTYR-1 (pigmented) ; and 4) LpcTYR-2 (pigmented) .
- FIG. 1 LpcTYR cells in culture. A nest of cells in the middle of the field contains large, pigmented cytoplasmic granules. Magnification x320.
- FIG. 1 Tremsmission election micrographs of segments of LpcTYR cells.
- FIG. 6 Expression of tyrosinase activity in cell extracts from: 1) SK-MEL 19 melanoma; 2) Lpc cells (transfected with pUC 18 plasmid); 3) LpcTYR-1 cells (transfected with BBTY-1 sense construct) 4) LpcTYR-2 cells (transfected with BBTY-1 sense construct) ; and 5) LpcTYW cells (transfected with a BBTY 1 antisense construct) .
- Tyrosine hydroxylase activity is expressed as (cpm 3 H 2 0/min/mg protein) rl "[bars! or (cpm 3 H 2 0/min/5xl0 6 cells) rI ⁇ V M bars] .
- FIG. 7 Immunoprecipitation of lysates from 35 S-methionine metabolically labeled SK-MEL-19 melanoma cells, LpcTYR-2 cells expressing BBTY-1, and L929 cells. Lanes: 1) mAb TA99; 2) mAb 2G10; 3) control rabbit sera; and 4) rabbit anti-tyrosinase antisera. A 75 kD band is detected in SK- MEL-19 (with TA99, 2G10 and anti-tyrosinase) and LpcTYR-2 cells (with anti-tyrosinase) . Molecular weight standards: Myosin M chain (200 kD) ; phosphorylase (96 D) ; bovine serum albumin (68 kD) ; and ovalbumin (43 kD) .
- Figure 8 Indirect immunofluorescence assays for antigen expression by: A) LpcTYR-2 cells expressing BBTY-1, and B) SK-MEL-19 melanoma cells.
- mAb TA99 anti-gp75
- mAb CF21 anti-melanoso al antigen •
- mAb H100-5R28 anti-H-2 k
- the present invention provides a non-melanocytic eucaryotic cell constitutively expressing biologically active human tyrosinase.
- biologically active human tyrosinase means a polypeptide having (1) an amino acid sequence identical to, or substantially identical to, the amino acid sequence of and (2) the biological activity of naturally occurring human tyrosinase.
- non-melanocytic eucaryotic cell means eucaryotic cell characterized by the absence of elanos ⁇ mes, that is, the organelles associated with the production of the polymeric pigment melanin.
- a fibroblast On example of such a cell is a fibroblast.
- any eucaryotic cell is useful in the practice - of the subject invention including without limitation, mammalian cells such as human cells for example fibroblast cells, the cells or other animals such as ovine, porcine, murine, bovine or avian cells, insect cells, or yeast cells.
- Useful non-melanocytic eucaryotic cells include eucaryotic cells in which DNA encoding biologically active human tyrosinase is not naturally present and into which such DNA has been introduced. Methods for introducing such DNA are well known to those skilled in the art as are methods for doing so under conditions such that the DNA will be expressed and biologically active human tyrosinase produced (43).
- the DNA encoding human tyrosinase is carried on an expression vector suitable for expression in the eucaryotic cell type involved.
- the expression vector may be a retrovirus; for an insect cell, the expression vector may be a baculovirus.
- nucleic acid encoding biologically active human tyrosinase may be used in this invention.
- One such DNA is DNA having the sequence shown in Figure 1 extending from nucleotide 58 to nucleotide 1593 (BBTY-1) .
- the non-melanocytic eucaryotic cell may be a mammalian cell such as a mouse or human fibroblast cell and may comprise a retroviral expression vector, for example, an expression vector which comprises an SV40 early region promoter and enhancer sequences, an initiation codon immediately upstream of the DNA encoding human tyrosinase, and a termination signal immediately downstream of the DNA encoding human tyrosinase.
- a retroviral expression vector for example, an expression vector which comprises an SV40 early region promoter and enhancer sequences, an initiation codon immediately upstream of the DNA encoding human tyrosinase, and a termination signal immediately downstream of the DNA encoding human tyrosinase.
- the non-melanocytic eucaryotic cell may be an insect cell and may comprise a baculovirus expression vector, for example, an expression vector which comprises DNA encoding biologically active human tyrosinase under the expressional control of a polyhydrin promoter (44) .
- a baculovirus expression vector for example, an expression vector which comprises DNA encoding biologically active human tyrosinase under the expressional control of a polyhydrin promoter (44) .
- the non-melanocytic eucaryotic cell may be a yeast cell and may comprise an expression plasmid, for example, an expression plasmid which comprises DNA encoding biologically active human tyrosinase under the expressional control of a suitable promoter such as the aleoiiol dehydrogenase isoenzyme I (ADH I) , the phosphoglycerol kinase (PGK) promoter, the repressible acid phosphatase (PH05) promoter and the a factor promoter (plus the signal sequence) .
- ADH I aleoiiol dehydrogenase isoenzyme I
- PGK phosphoglycerol kinase
- PH05 repressible acid phosphatase
- non- melanocytic eucaryotic cells which constitutively produces biologically active human tyrosinase produces melanin.
- This invention also provides a method for producing a biologically active human tyrosinase which comprises culturing the cells described hereinabove under conditions such that, the cells express the biologically active human tyrosinase and recovering the human tyrosinase so expressed.
- Conditions for culturing the cells and for recovering the biologically active human tyrosinase are known in the art and vary depending upon the nature of the eucaryotic cell, expression vector (i any) and the like.
- This invention also provides a method for producing a biologically active human tyrosinase which comprises culturing the cells described hereinabove under conditions such that the cells express the biologically active human tyrosinase and recovering the human tyrosinase so expressed.
- a biologically active human tyrosinase which comprises culturing the cells described hereinabove under conditions such that the cells express the biologically active human tyrosinase and recovering the human tyrosinase so expressed.
- melanin which comprises culturing eucaryotic cells under conditions such that the cells express biologically active human tyrosinase and the tyrosinase so expressed catalyzes the production of melanin, and then recovering the melanin so produced.
- TK " L929 cells (mouse fibroblast) (3) were used for transfection experiments.
- Cell lines were maintained in Eagle's Minimum Essential Medium supplemented with 2 mM glutamine, O.lmM non-essential amino acids, 100 U/ml penicillin, 0.1 mg/ml streptomycin and 10% fetal bovine serum (complete medium) .
- Cells were passaged with trypsin (1 mg/ml and EDTA (0.2 mg/ml). All cultures were checked regularly for the presence of mycoplasma and contaminated cultures were discarded.
- Cell pellets were fixed in Karnofsky's fixative overnight, rinsed in PBS for 1 hour, then post-fixed for 1 hour in 1% osmium tetroxide-PBS solution.
- Cell pellets were dehydrated in graded ethyl alcohol followed by propylene oxide, and embedded in Maraglas-D.E.R. 732 epoxy resin (Dow Chemical Co., Midland, Michigan).
- 1 ⁇ m thick sections were stained with borate-buffered 1% toluidine blue. Thin sections were stained with uranyl acetate followed by lead citrate and examined with a Philips 410 LS electron microscope.
- cpNJ Library cfflfl $creepjpg t A cDNA library was constructed from 3 ⁇ g of poly(A+) selected mRNA (4) prepared from the human melanotic melanoma cell line S_. ⁇ -MEL-19 (2) . Full length cDNA was synthesized, rendered blunt-ended using Klenow enzyme, and tailed with EcoRI linkers (New England Biolabs, Inc., Beverly, MA) (5). The cDNA was then size-fractionated on Ultrogel Aca 34 (Pharmacia Fine Chemicals, Piscataway, NJ) (6).
- cDNA molecules > 800 bp were used to construct a library of 3 x 10 5 recombinants in the lambda phage vector gtl0(7).
- a 50 base oligonucleotide probe 50-mer, shown below
- a 50 base oligonucleotide probe 50-mer, shown below
- the oligonucleotide was synthesized on an Applied Biosystem DNA synthesizer, model 310 A (Applied Biosystems, Foster City, CA) .
- the probe was end-labeled with gamma 3 P-ATP and T4 polynucleotide kinase (4) .
- Prehybridization and hybridization were carried out at 48°C for 4 hours and 18 hours, respectively, in 6x NET (lx NET is 0.15M NaCl, l mM EDTA, and 15mM Tris-HCl, pH 8) , 0.1% SDS and 5x Denhardt's solution (0.1% BSA, 0.1% Ficoll 400, 0.1% polyvinyl- pyrolidone) , and 100 ⁇ g/ml of denatured salmon sperm DNA.
- Duplicate filters were washed in 6x NET, 0.1% SDS at room temperature, followed by stringent washes at 55° and 60°C. The filters were then autoradiographed for 4 hours at -70°.
- Plaque purified phage DNA was restricted with EcoRI and cDNA inserts were subcloned into the plasmid vector pUC 18(8). Recombinant plasmids and deletion subclones subsequently obtained by digestion with exonuclease IIl/Mung Bean nuclease (9) were sequenced by the dideoxynucleotide chain termination method (10) . Northern Blot Analysis.
- Poly (A+)-mRNA (4 ⁇ g) was fractioned on 1% formaldehyde denaturing agarose gels (4) , transferred of Gene Screen Plus membranes (Dupont, New England Nuclear, Boston, MA) , and hybridized to a ⁇ P-labeled cDNA probe.
- the filters were washed twice at room temperature in 2x SSC (IX SSC is 0.15M NaCl, 0.015 M sodium citrate pH 7) and 1% SDS, then stringent washes were carried out at 55 ⁇ C in IX SSC, 1% SDS, and at 65°C in 0.1X SSC, 1% SDS, for 15 minutes each.
- the cDNA inserts were subcloned into the EcoRI site of the expression vector pcEXV-3, which allows expression of cDNA under the control of SV40 early region promotor and enhancer sequences (11) .
- Expression plasmids containing cDNA inserts in opposite orientations (5'—> 3' or 3'—> 5') were constructed.
- Sense and antisense oriented plasmids were designated pcTYR and pcTYW, respectively.
- L929 cells were cotransfected by the calcium phosphate precipitation technique (12) with the following combinations: (1) transfection with pUC 18, pSV2 neo plasmid, and high molecular weight carrier DNA from L929 cells; (2) transfection with pcTYR, pSV2 neo plasmid, and high molecular weight carrier DNA from L929 cells; or (3) transfection with pcTYR, pSV2 neo plasmid, and high molecular weight carrier DNA from L929 cells.
- transfectants were started on day 3 following transfection with 1 mg/ml of the antibiotic G418 (Sigma Chemical Co., St. Louis, MO) . Complete medium with G418 was replaced every 3 days and colonies appearing on days 10-14 were isolated using cloning rings and expanded.
- the mouse origin of transfected cell lines was confirmed by positive anti-mouse Ig mixed hemadsorption assays using H-100-5R28, a monoclonal antibody directed against H-2K k (mouse MHC class I antigens) (13), and lack of reactivity with mAb M3- 68 (14) or AJ2 (15) which recognize virtually all human melanoma cells but not L929 cells.
- CF21 (igGl) and TA 9 (IgG2a) are mAb which have been previously described that recognize distinct antigens in human melanosomes (16) .
- the monoclonal antibody 2G10 (IgG2a) recognizes a 75 kD intracellular glycoprotein of pigmented melanotic cells (17) .
- mAb AJ2 (IgGl) recognizes the beta subunit of human VLA/integrin molecules (15, 18).
- Rabbit anti-tyrosinase antiserum was raised by immunization with purified mouse tyrosinase (19) .
- Tyrosinase was purified by DEAE ion exchange chromatography followed by sequential discontinuouspolyacrylamidegelelectrophoresis.
- Anti-mouse immunoglobulin hemadsorption assays and indirect immunofluorescence studies were performed as described (2, 20) .
- 3X10 6 cells were solubilized in 0.5 ml Protosol (NEN, DuPont, Boston, MA) and kept on ice for 2 hours.
- An absorption baseline was established using Protosol, and absorption spectra for cell extracts were determined between 320-450 ⁇ m and compared against a melanin control 100 ⁇ g/ml, in Protosol.
- cDNA clones were isolated from a lambda gtlO library derived from the pigmented human melanoma cell line SK-MEL-19 (see Materials and Methods) . 10 s recombinant cDNA clones were screened and four reactive clones were plaque purified. The four cDNA inserts were subcloned into the plasmid vector pUC 18 and clones were designated pBBTY-1, -2, -3, and -4.
- pBBTY-1 and pBBTY-2 Two clones, pBBTY-1 and pBBTY-2, each containing cDNA inserts of 2 kb, had restriction maps identical to each other and to that of Pmel 34 reported by Kwon et al. (1) (digested with Bgl II, Hpa II, Msp I, Neo I, Pvu II, and Taq I).
- the cDNA inserts in clones pBBTY-3 and pBBTY-4 were 1.7 and 1.8 kb, respectively.
- the restriction map of pBBTY-3 was different from those of pBBTY-1 and pBBTY-2 downstream of position 960 (a PvuII restriction site) .
- pBBTY-1 was subsequently sequenced and used for further experiments.
- the nucleotide sequence of BBTY-1 (Fig. 1) contained a single open reading frame of 1593 residues capable of encoding a 531 amino acid (aa) polypeptide with a derived molecular weight of 60.37 kD. A leader peptide of 19 aa was assigned to positions -19 through -1 (23). The processed core protein was predicted to have a molecular weight of 58.118 kD. Seven potential N-glycosylation signals (Asn-X- Ser/Thr) were predicted at positions 69, 94, 144, 213, 273, 320, and 354.
- BBTY-1 was a candidate for a full length cDNA clone encompassing a complete coding region.
- BBTY-1 cDNA was used to detect mRNA transcripts in Northern blot analysis of a panel of melanoma cell lines, including those known to express tyrosinase activity as well as tyrosinase-negative melanomas.
- the major transcript detected was 2.4 kb, but a weaker signal was seen at 4.7 kb ( Figure 2) .
- BBTY-l was transfected into L929 mouse fibroblasts using the expression vector pcEXV-3 (11) .
- L929 cells transfected with pcTYR sense orientation
- Control cells transfected with pcTYW antisense orientation
- LpcTYW antisense orientation
- LpC plasmid pUC 18
- LpcTYR cells contained pigment, while no pigmentation was detected in LpcTYW, LpC or untransfected L929 cells.
- the cell pellets of LpcTYR clones were dark brown in contrast to the non-pigmented pellets of LpcTYW and LpC cultures.
- LpcTYR Cell pellets of LpcTYR were more deeply pigmented when cultures were harvested at confluency. LpcTYR clones have continued to produce pigment for more than 5 months in continuous culture.
- absorption spectra of cell extracts from LpcTYR and control L929 cells were compared to those of extracts of the pigmented melanoma cell line SK-MEL-19 and purified melanin.
- LpcTYR and SK- MEL-19 extracts and melanin had identical patterns of absorption, with broad absorption from 360 nm to >450 nm; this absorption pattern was not observed with L929 cell extracts.
- the absorption patterns by extracts of LpcTYR and SK-MEL-19 and melanin standard were identical to the previously described absorption spectra for melanin (26) .
- LpcTYR cells but not control LpC cells, had cytoplasmic membrane-bound vesicles (Fig. 5) containing electron dense material consistent with melanin. There was no evidence of melanosomal structural elements within LpcTYR cells or Lpc cells.
- tyrosine hydroxylase activity was measured in protein extracts of subclones of LpcTYR, LpcTYW and LpC.
- extracts of LpcTYW and LpC contained no detectable tyrosinase activity.
- ⁇ _ LpcTYR-2, SK-MEL-19 melanoma cells and control L929 cells were metabolically labeled with 35 S-methionine and cell extractswere immunoprecipitatedwithrabbit anti-tyrosinase antiserum or mAb TA99 (which detects the melanosomal antigen gp75) .
- mAb 2G10 which is also directed against an intracellular 75 kD antigen expressed by pigmented melanoma cells (17) was tested.
- Anti-tyrosinase antiserum detected a 75 kD protein in LpcTYR-2 cells and a protein of the same size in SK-MEL-19 melanoma cells (Fig. 7) .
- the molecular size of tyrosinase in LpcTYR-2 and SK-MEL-19 cells corresponded to the size of glycosylated tyrosinase.
- a very faint band at approximately 75 kD was inconsistently detected in L929 cells with anti-tyrosinase antiserum - this likely represents a cross-reaction of poly ⁇ lonal sera to a non-tyrosinase molecule in L929 cells since no tyrosinase activity or tyrosinase transcript was detected in these cells and cold lysates from L929 cells did not block immunoprecipitation of tyrosinase from LpcTYR-2.
- Tyrosinase catalyzes the o-hydroylyation of monophenols and oxidation of o.-diphenols to o_-guinones.
- tyrosinase enzymatically converts tyrosine to dihydroxyphenylalanine (DOPA) and DOPA to dopaquinone, leading to the spontaneous formation of the complex mixture of pigments known as melanin (27) .
- DOPA dihydroxyphenylalanine
- melanin melanin
- the later steps in this pathway are not well characterized, and it has been suggested that a number of other factors, both catalytic and inhibitory, may regulate melanin synthesis and influence the species of melanin formed (28, 29).
- the complexity of pigment expression has been further highlighted by genetic studies in the mouse where more than 50 loci have been found to influence coat color (30) . Thus, it is possible that a number of gene products, most not yet identified, can play a role in elanogenesis.
- transfected L929 fibroblasts not only stably expressed tyrosinase activity but were able to produce and package melanin.
- Melanin precursors are cytotoxic, and it has been presumed that melanocytic cells containmechanisms, perhaps located within melanosomes, that protect from the effects of toxic intermediates.
- Melanin precursors were cytotoxic in transfected L929 cells, and that cells producing substantial amounts of pigment were destined to die, based on the following observations: (1) only a subpopulation of transfected cells contained pigmented vesicles; (2) deeply pigmented, non-viable cells were observed floating in the supernatant of transfectant cultures; and (3) when transfected cells were cryopreserved and then thawed, pigmented cells were not initially detected but eventually repopulated the culture.
- human tyrosinase is glycosylated to a form identical in size to fully processed tyrosinase expressed in human melanocytic cells. It is likely that human tyrosinase was processed through the Golgi apparatus in L929 cells and transported to or remaining in vesicles arising from the trans Golgi. The nature and destination of these vesicles is not known. It is interesting to speculate that these vesicles might be precursors of melanosomes but that formation of melanosomes would depend on the products of other specialized genes.
- tyrosinase The expression and regulation of tyrosinase has been the subject of extensive studies, but the formal identification of the gene that codes for tyrosinase has not been straightforward (reviewed in 31) .
- Two distinct, and distantly related, genes have been proposed as candidates for mouse tyrosinase, based on detection of mRNA of these genes in melanocytic cells and reactivity of the protein product with antibodies against tyrosinase (32, 33). Neither gene, however, was demonstrated to directly code for a product with tyrosinase activity.
- the Pmel 34 cDNA clone was detected by screening a cDNA library with polyclonal antisera raised against hamster tyrosinase.
- Pmel 34 has - ⁇ . been mapped to the c-albino locus in the mouse, the presumed site of the tyrosinase structural gene or a gene that regulates tyrosinase expression.
- the nucleotide and predicted aa sequences of BBTY-1 and Pmel 34 are closely similar, except BBTY-1 contains an initiation codon that is not present in Pmel 34. Additionally, there are minor differences in nucleotide and predicted aa sequences.
- transcripts of the tyrosinase gene have been found . in mouse melanoma cells (36) .
- the remaining transcripts are generated by alternative splicing leading to deletion of internal sequences, presumably by exon skipping or by selection of internal splice sites.
- these alternative transcripts have been expressed, they have not been found to encode active tyrosinase (34, 36).
- the BBTY-1 cDNA represents the human counterpart of the mouse pmcTyrl transcript.
- Another cDNA clone which was isolated, BBTY-3 differs from BBTY-1 in its 3* restriction map, possibly corresponding to an alternative transcript of the human tyrosinase gene.
- mAb 2G10 immunodepletes tyrosinase activity (37) and therefore possibly recognizes a molecule with tyrosinase activity.
- mAb 2G10 did not react with human tyrosinase encoded by BBTY-1, suggesting that mAb 2G10 recognizes a distinct molecule from the gene product of BBTY-1.
- TA99 mAb recognizes an acidic 75 kD glycoprotein (38) , and the antigen recognized by TA99 is a candidate for tyrosinase, based on its expression in melanosomes, its molecular size and charge.
- the finding that mAb TA99 and CF21 did not react with L929 transfectants provides evidence that they do not recognize determinants coded for by the BBTY-1 human tyrosinase molecule.
- mAb TA99 does not recognize tyrosinase: 1) mAb TA99 does not precipitate tyrosinase activity from melanoma cell extracts (39, 40); 2) the TA99 antigen, gp75, is generally co- expressed with tyrosinase activity, but there are examples of gp75* melanoma cell lines that do note express tyrosinase activity; and 3) the expression of tyrosinase and gp75 in melanoma cell lines has been independently regulated (20) .
- a distinguishing characteristic of cells of the melanocyte lineage is the expression of the melanosomal enzyme tyrosinase which- catalyzes the synthesis of the pigment melanin.
- a tyrosinase cDNA clone, designated BBTY-1 was isolated from a library constructed from the pigmented TA99 + /CF21 + melanoma cell line SK-MEL-19, Expression of BBTY-1 in mouse L929 fibroblasts led to synthesis and expression of active tyrosinase, and, unexpectedly, to stable production of melanin. Melanin was synthesized and stored within membrane-bound vesicles in the cytoplasm of transfected fibroblasts.
- BBTY-1 detected a 2.4 kb mRNA transcript in 9 of 9 pigmented, tyrosinase-positive melanoma cell lines. Tyrosinase transcripts of the same size were detected in a subset (3 of 8) of non-pigmented, tyrosinase- negative .melanoma cell lines, suggesting that post- transcriptional events are important in regulating tyrosinase activity.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Cette invention concerne une cellule eucaryote non melanocytique exprimant de manière constitutive la tyrosinase humaine biologiquement active. La présente invention concerne également des procédés de production de tyrosinase humaine biologiquement active. De plus, l'invention concerne une cellule eucaryote non mélanocytique qui exprime de manière constitutive la tyrosinase humaine biologiquement active qui, à son tour, catalyse la production de mélanine. La mélanine ainsi produite peut alors être récupérée.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34396089A | 1989-04-26 | 1989-04-26 | |
US343960 | 1999-06-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0507772A4 EP0507772A4 (fr) | 1992-06-11 |
EP0507772A1 true EP0507772A1 (fr) | 1992-10-14 |
Family
ID=23348412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP90907793A Withdrawn EP0507772A1 (fr) | 1989-04-26 | 1990-04-26 | Cellule eucaryote non melanocytique exprimant de maniere constitutive la tyrosinase humaine biologiquement active, et son utilisation |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0507772A1 (fr) |
JP (1) | JPH04505249A (fr) |
CA (1) | CA2054709A1 (fr) |
WO (1) | WO1990012869A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6613281B2 (en) | 1998-05-08 | 2003-09-02 | Edwards Lifesciences Corporation | Integrated heat exchanger/reservoir |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5487974A (en) * | 1992-12-22 | 1996-01-30 | Ludwig Institute For Cancer-Research | Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells |
ATE215830T1 (de) * | 1992-12-22 | 2002-04-15 | Ludwig Inst Cancer Res | Verfahren zur detektion und behandlung von individuen mit abnormal hla-a2/tyrosinase- peptidantigenen exprimierenden zellen |
US5571711A (en) * | 1993-06-17 | 1996-11-05 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors |
US6300057B1 (en) * | 1997-02-06 | 2001-10-09 | Large Scale Biology Corporation | Melanins with improved ability to inhibit HIV replication |
TW200718944A (en) * | 1999-06-29 | 2007-05-16 | Univ New York | Screening methods for compounds that affect melanogenesis |
CN1312375A (zh) * | 2000-03-07 | 2001-09-12 | 上海博德基因开发有限公司 | 一种新的多肽——人酪氨酸酶12和编码这种多肽的多核苷酸 |
WO2014016118A1 (fr) | 2012-07-26 | 2014-01-30 | Unilever N.V. | Méthode de préparation d'une tyrosinase humaine recombinée |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988002372A1 (fr) * | 1986-10-06 | 1988-04-07 | Donald Guthrie Foundation For Medical Research, In | CLONE D'ADNc DE TYROSINASE HUMAINE |
-
1990
- 1990-04-26 EP EP90907793A patent/EP0507772A1/fr not_active Withdrawn
- 1990-04-26 WO PCT/US1990/002288 patent/WO1990012869A1/fr not_active Application Discontinuation
- 1990-04-26 JP JP2507117A patent/JPH04505249A/ja active Pending
- 1990-04-26 CA CA002054709A patent/CA2054709A1/fr not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988002372A1 (fr) * | 1986-10-06 | 1988-04-07 | Donald Guthrie Foundation For Medical Research, In | CLONE D'ADNc DE TYROSINASE HUMAINE |
Non-Patent Citations (3)
Title |
---|
NUCLEIC ACIDS RESEARCH. vol. 14, no. 6, 25 March 1986, ARLINGTON, VIRGINIA US pages 2413 - 2427; SHIBAHARA, S. ET AL.: 'Cloning and expression of cDNA encoding mouse tyrosinase' * |
See also references of WO9012869A1 * |
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE vol. 156, no. 4, December 1988, SENDAI, JP pages 403 - 414; SHIBAHARA, S. ET AL.: 'Molecular basis for the heterogeneity of human tyrosinase' * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6613281B2 (en) | 1998-05-08 | 2003-09-02 | Edwards Lifesciences Corporation | Integrated heat exchanger/reservoir |
Also Published As
Publication number | Publication date |
---|---|
EP0507772A4 (fr) | 1992-06-11 |
JPH04505249A (ja) | 1992-09-17 |
CA2054709A1 (fr) | 1990-10-27 |
WO1990012869A1 (fr) | 1990-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bouchard et al. | Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA. | |
Galjart et al. | Expression of cDNA encoding the human “protective protein≓ associated with lysosomal β-galactosidase and neuraminidase: Homology to yeast proteases | |
Rosemblat et al. | Identification of a melanosomal membrane protein encoded by the pink-eyed dilution (type II oculocutaneous albinism) gene. | |
Sarangarajan et al. | Tyrp1 and oculocutaneous albinism type 3 | |
Vijayasaradhi et al. | Intracellular sorting and targeting of melanosomal membrane proteins: identification of signals for sorting of the human brown locus protein, gp75. | |
Avraham et al. | Characterization and expression of the human rhoH12 gene product | |
Jackson | Homologous pigmentation mutations in human, mouse and other model organisms | |
HEARING et al. | Analysis of mammalian pigmentation at the molecular level | |
Winder et al. | The mouse brown (b) locus protein has dopachrome tautomerase activity and is located in lysosomes in transfected fibroblasts | |
AU665932B2 (en) | A novel onco-fetal gene, gene product and uses therefor | |
Kammerer et al. | The human bradykinin B2 receptor gene: Full-length cDNA, genomic organization and identification of the regulatory region | |
Sullivan et al. | Expression of a connexin 43/beta-galactosidase fusion protein inhibits gap junctional communication in NIH3T3 cells. | |
Eychène et al. | Chromosomal assignment of two human B-raf (Rmil) proto-oncogene loci: B-raf-1 encoding the p94" and B-raf-2, a processed pseudogene | |
EP0507772A1 (fr) | Cellule eucaryote non melanocytique exprimant de maniere constitutive la tyrosinase humaine biologiquement active, et son utilisation | |
AU679432B2 (en) | DNA encoding a glycine transporter and uses thereof | |
Mochii et al. | Isolation and characterization of a chicken tyrosinase cDNA | |
US5312733A (en) | Developmental marker gene of CD4-CD8 thymocytes | |
Tomita et al. | The monoclonal antibodies TMH-1 and TMH-2 specifically bind to a protein encoded at the murine b-locus, not to the authentic tyrosinase encoded at the c-locus | |
US5773291A (en) | Non-melanotytic mammalian cell constitutively expressing biologically active human tyrosinase and use thereof | |
Minoru et al. | Cloning and sequencing of the cDNA encoding tyrosinase of the Japanese pond frog, Rana nigromaculata | |
US5679511A (en) | CDNA clones for a regulatory protein in the melanin-production pathway | |
US6168946B1 (en) | gp75 as a tumor vaccine for melanoma | |
Gesualdo et al. | Molecular cloning of a peroxidase mRNA specifically expressed in the ink gland of Sepia officinalis | |
AU691592B2 (en) | Gene encoding cationic amino acid transporter protein | |
Fulcher et al. | Characterization of laminin receptor messenger ribonucleic acid and protein expression in mouse spermatogenic cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19911125 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE |
|
17Q | First examination report despatched |
Effective date: 19941013 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19950425 |